|
T-Bren, Dose level 1 Clinical Trials
1 actively recruiting trial across 1 location
Also known as: BL-M07D1, T-Bren, Trastuzumab Brengitecan
Pipeline
Phase 3: 1
Top Sponsors
- SystImmune Inc.1
Indications
- Urothelial Carcinoma of the Urinary Bladder1
- Bladder Ca1
- Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable1
- Bladder Cancer (BC)1
- Bladder Cancer Recurrent1
Macon, Georgia1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.